MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Drug-Device Combinations / Taris reboots with $32m round for bladder tech

Taris reboots with $32m round for bladder tech

October 27, 2015 By Brad Perriello Leave a Comment

Taris BiomedicalA year after dealing its Liris bladder treatment to Allergan in a deal worth up to $588 million, Taris Biomedical raised another $32 million to put toward the implant, which is designed to deliver drugs directly to the bladder.

Allergan paid $67.5 million in cash in August 2014 for Liris, a drug-device combination designed to deliver lidocaine to treat interstitial cystitis, or bladder pain syndrome. The deal also included $295 million in development milestones and another $225 million in commercial milestones.

Today Taris said it’s planning to investigate other treatments using the same implant used in Liris, funded with a $32 million round led by prior backer Flagship Ventures, joined by existing investor Polaris Venture Partners and a new backer, RA Capital Management.

“The sale to Allergan of our clinical-stage treatment for interstitial cystitis in 2014 was an important validation of our revolutionary approach to treating bladder diseases,” president & CEO Purnanand Sarm said in prepared remarks. “Since then we have been working hard to build a high value therapeutically-focused urology company on this foundation. This new funding will enable us to launch multiple clinical trials over the next 12 months and further expand our team.”

Taris plans to explore treatments for bladder cancer and overactive bladder segments. Sarma told Xconomy that the bladder cancer drug the company is looking at is off-patent and free to test. The OAB drug, also already in use, would be delivered at a much lower dose, Sarma told the website. Four clinical programs are on tap for 2016, he said, with results due late in the year.

“We could do Allergan-like transactions again and again,” Sarma said.

Taris also built out its board and and clinical operation, naming Flagship Ventures managing partner Ed Kania, former Allergan exec Kevin Finney and ex-Civitas CEO Mark Iwicki to its board. The YY-based company also tapped Dr. Christopher Cutie, M.D., of the Mass. General Hospital, to be vice president of clinical development.

“Taris combines the experience and success of an established company with the agility and sense of mission of a startup. We are pleased to join existing and new finance partners as we help Taris advance its technology to help millions of patients who suffer from bladder diseases,” Kania said.

Filed Under: Drug-Device Combinations, Funding Roundup Tagged With: Taris Biomedical, Venture Capital/Private Equity

In case you missed it

  • Caresyntax to acquire Syus; raises $45.6m
  • Nihon Kohden launches new patient monitor
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • Iradimed renews CE mark for MRI-safe patient monitor
  • Flexicare recalls fiber optic laryngoscope blades and handles
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • TransEnterix announces reverse split of common stock
  • GI Windows raises $15m Series A
  • ImpediMed lands expanded 510(k) clearance for Sozo
  • Haemonetics opens new Boston headquarters
  • Employees say Intuitive Surgical, J&J, Stryker best places to work in 2020
  • Eitan Group signs service agreement with Integrated Medical Systems
  • Beta Bionics’ bionic pancreas wins breakthrough status from FDA
  • Sanofi backs away from diabetes partnership with Verily
  • FDA clears Cochlear piezoelectric hearing implant
  • Biolase lands 510(k) for dental hygiene laser
  • Mayo Clinic, W.L. Gore team up on stem cell therapy treatments

RSS From Medical Design & Outsourcing

  • RSNA 2019: 7 radiology innovations you need to know
    Nearly 53,000 people attended the 2019 Radiological Society of North America annual meeting in Chicago last week. And they heard the same acronym over and over again: AI. Exhibitors at the conference touted their artificial-intelligence-enhanced technology at every turn, claiming to make images clearer, sharper, easier to use and powerful enough to help clinicians make… […]
  • Employees say Intuitive Surgical, J&J, Stryker best places to work in 2020
    Intuitive Surgical (NSDQ:ISRG), Johnson & Johnson (NYSE:JNJ) and Stryker (NYSE:SYK) were recently named as Glassdoor’s employees’s choice of Best Places to Work in 2020. Each year, Glassdoor uses feedback that employees have shared on the website over the past year to compile a list of the best places to work in 2020. Employee reviews provide Glassdoor with insights into job and… […]
  • Biolase lands 510(k) for dental hygiene laser
    Biolase (NSDQ:BIOL) this week announced it has received FDA 510(k) clearance for its Epic Hygiene dental laser. The laser system allows dental hygienists to manage non-surgical periodontitis and increase clinical production. It offers a step-by-step clinical protocol with pocket therapy and perio debridement for easy implementation. Get the full story on our sister site, MassDevice. The […]
  • Mayo Clinic, W.L. Gore team up on stem cell therapy treatments
    Mayo Clinic and W. L. Gore & Associates have announced a partnership to develop implantable cell therapies to treat debilitating conditions with no cure. The for-profit company, Avobis Bio, will combine a patient’s own stem cells with bioabsorbable scaffolds to stimulate the healing of perianal fistulas, painful tunneling wounds that affect patients with Crohn’s disease.… […]
  • Toray Industries touts polymer optical fiber
    Toray Industries said today that its Raytela polymer optical fiber provides for high-quality imaging in the minimally invasive medical device market. Raytela can negotiate tight 9mm radius bends, making it useful for devices used in endoscopy, uretroscopy, ophthalmic surgery and other procedures that require smaller devices that can navigate more tortuous paths than previously available,… […]
  • Report: EtO blood levels higher in Illinois neighbors of Medline sterilization plant
    This article has been updated with comments from Medline Industries. People who live about a mile away from a Medline device sterilization plant in Waukegan, Ill. have blood levels of the cancer-causing gas ethylene oxide that are about 50% higher than those who live farther away, according to a report by WebMD and Georgia Health… […]
  • Glooko gains ISO certification for California, Sweden sites
    Diabetes software company Glooko announced today that its Mountain View, Calif., and Gothenburg, Sweden, sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services. ISO 13485 describes the requirements for comprehensive practices and procedures for the design, development, production and delivery of medical devices, including digital health software. To become ISO… […]
  • FDA details framework for abbreviated 510(k) medical device review pathway
    By Stewart Eisenhart, Emergo Group The US Food and Drug Administration has published a high-level framework for its Safety and Performance Based Pathway, an expedited 510(k) premarket review process for qualifying medical devices announced earlier in 2019. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
  • Drug or device? FDA loses this argument for now
    This article has been updated with comments from an attorney for Genus Medical Technologies. A federal judge has temporarily blocked an attempt by the FDA to regulate a barium sulfate product ingested before imaging as a drug. The decision counts as at least a partial win for Genus Medical Technologies (St. Louis), maker of the… […]
  • Greenlight Guru updates change management capabilities of QMS
    Greenlight Guru said today that it has added updates to the change management capabilities 
of its medical device quality management system (MDQMS). The update was designed to improve traceability and efficiency associated with product and process changes, according to the Indianapolis-based company. It includes advanced workflow efficiencies to identify, assess and track the items affected… […]
  • Medical device excise tax would reduce R&D spending, report says
    The medical device excise tax will reduce research and development spending and impede innovation if reinstated in 2020, according to a report from Minnesota trade group Medical Alley Association. In the report, Medical Alley surveyed its members that will be affected by the return of the tax on Jan. 1, 2020. About 83% of survey respondents… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS